Data-Driven Decision-Making for Medications Management Modalities

157514-Thumbnail Image.png
Description
One of the critical issues in the U.S. healthcare sector is attributed to medications management. Mismanagement of medications can not only bring more unfavorable medical outcomes for patients, but also imposes avoidable medical expenditures, which can be partially accounted for

One of the critical issues in the U.S. healthcare sector is attributed to medications management. Mismanagement of medications can not only bring more unfavorable medical outcomes for patients, but also imposes avoidable medical expenditures, which can be partially accounted for the enormous $750 billion that the American healthcare system wastes annually. The lack of efficiency in medical outcomes can be due to several reasons. One of them is the problem of drug intensification: a problem associated with more aggressive management of medications and its negative consequences for patients.

To address this and many other challenges in regard to medications mismanagement, I take advantage of data-driven methodologies where a decision-making framework for identifying optimal medications management strategies will be established based on real-world data. This data-driven approach has the advantage of supporting decision-making processes by data analytics, and hence, the decision made can be validated by verifiable data. Thus, compared to merely theoretical methods, my methodology will be more applicable to patients as the ultimate beneficiaries of the healthcare system.

Based on this premise, in this dissertation I attempt to analyze and advance three streams of research that are influenced by issues involving the management of medications/treatments for different medical contexts. In particular, I will discuss (1) management of medications/treatment modalities for new-onset of diabetes after solid organ transplantations and (2) epidemic of opioid prescription and abuse.
Date Created
2019
Agent

No Vehicle, No Aid: A Literature Review of Humanitarian Aid Logistics and Vehicle Fleet Management

132936-Thumbnail Image.png
Description
As a part of the supply chain alternative thesis project, various research seminars were attended to understand various topics relevant to the supply chain academic community. After attending these seminars, the topic of humanitarian aid logistics and vehicle fleet management

As a part of the supply chain alternative thesis project, various research seminars were attended to understand various topics relevant to the supply chain academic community. After attending these seminars, the topic of humanitarian aid logistics and vehicle fleet management was selected for review. In order to understand humanitarian logistics, its relevance, and its path forward, a comprehensive literature review was completed to address its current status. Through research and analysis of ten academic studies, four common themes were addressed. Last mile logistics and procurement management styles were two underlying themes or areas of improvement throughout most academic studies. It was found in the majority of studies, various types of statistical modelling were used to prove hypotheses supporting improvement in last mile logistics and procurement management styles. Lastly, among academic studies, interviews and commentary supplied by actual field employees analyzed the feasibility of real-world implementation of proposed solutions. It was concluded that while focusing on improvements related to successful last mile deliveries and procurement management styles are relevant to bettering commercial supply chains, solutions for humanitarian aid logistics must be more specific, microlevel to address the complex needs of each organization. It was also recommended that academic researchers work to close communication and knowledge gaps between themselves and practitioners, in order to provide better context for the problems they attempt to solve.
Date Created
2019-05
Agent

Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients

128921-Thumbnail Image.png
Description

Background: Hyperglycemia following solid organ transplant is common among patients without pre-existing diabetes mellitus (DM). Post-transplant hyperglycemia can occur once or multiple times, which if continued, causes new-onset diabetes after transplantation (NODAT).

Objective: To study if the first and recurrent incidence of

Background: Hyperglycemia following solid organ transplant is common among patients without pre-existing diabetes mellitus (DM). Post-transplant hyperglycemia can occur once or multiple times, which if continued, causes new-onset diabetes after transplantation (NODAT).

Objective: To study if the first and recurrent incidence of hyperglycemia are affected differently by immunosuppressive regimens, demographic and medical-related risk factors, and inpatient hyperglycemic conditions (i.e., an emphasis on the time course of post-transplant complications).

Methods: We conducted a retrospective analysis of 407 patients who underwent kidney transplantation at Mayo Clinic Arizona. Among these, there were 292 patients with no signs of DM prior to transplant. For this category of patients, we evaluated the impact of (1) immunosuppressive drugs (e.g., tacrolimus, sirolimus, and steroid), (2) demographic and medical-related risk factors, and (3) inpatient hyperglycemic conditions on the first and recurrent incidence of hyperglycemia in one year post-transplant. We employed two versions of Cox regression analyses: (1) a time-dependent model to analyze the recurrent cases of hyperglycemia and (2) a time-independent model to analyze the first incidence of hyperglycemia.

Results: Age (P = 0.018), HDL cholesterol (P = 0.010), and the average trough level of tacrolimus (P<0.0001) are significant risk factors associated with the first incidence of hyperglycemia, while age (P<0.0001), non-White race (P = 0.002), BMI (P = 0.002), HDL cholesterol (P = 0.003), uric acid (P = 0.012), and using steroid (P = 0.007) are the significant risk factors for the recurrent cases of hyperglycemia.

Date Created
2015-11-09
Agent